The most recently completed dexpramipexole clinical trial was EXHALE-1 (AS201), a Phase II clinical trial in participants with moderate-to-severe eosinophilic asthma. Dexpramipexole demonstrated highly significant, dose dependent eosinophil lowering during the primary assessment phase and was maximal at Week 12. Dexpramipexole produced clinically relevant changes in FEV across study arms and time points and the magnitude of FEV improvement was comparable to currently approved biologics. Dexpramipexole was well tolerated in the trial, with adverse events balanced across treatment and placebo groups, no serious adverse events, and no adverse events leading to discontinuation.